# A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders

> **NCT06705530** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Research Center for Hematology, Russia** · enrollment: 58 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma, B-cell
- Acute Lymphoblastic Leukemia ALL

## Interventions

- **BIOLOGICAL:** Hem101

## Key facts

- **NCT ID:** NCT06705530
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-26
- **Primary completion:** 2025-10-17
- **Final completion:** 2025-11-17
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705530, "A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06705530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*